The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Management of Liver Cirrhosis

간경변 환자의 관리

  • Lee, Chang-Hyeong (Department of Internal Medicine, Catholic University of Daegu School of Medicine)
  • 이창형 (대구가톨릭대학교 의과대학 내과학교실)
  • Published : 2012.02.01
⟨ Previous Next ⟩

Abstract

Liver cirrhosis has distortion of the hepatic architecture and the formation of regenerative nodules due to progressive hepatic fibrosis. Treatment of underlying etiology can slow or reverse the progression of liver fibrosis. Early stage is characterized by asymptomatic phase, termed 'compensated cirrhosis' follwed by the development of complications of portal hypertension and/or liver dysfunction, termed 'decompensated cirrhosis'. The quality of life and survival of patients with cirrhosis can be improved by prevention and treatment of these complications. This review discuss the complication and its management in patients with liver cirrhosis.

Keywords

References

  1. Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 2006;101:2511-2519. https://doi.org/10.1111/j.1572-0241.2006.00874.x
  2. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609-615. https://doi.org/10.1053/jhep.2002.31354
  3. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-1661. https://doi.org/10.1002/hep.510290608
  4. Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997;25:307-312. https://doi.org/10.1002/hep.510250209
  5. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48(Suppl 1):S93-S103.
  6. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-599. https://doi.org/10.1136/gut.2006.113050
  7. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58.

Cited by

  1. 간경변증 환자 음주행위 관련변인 -음주행위와 질병관련 변인의 융복합 측면- vol.13, pp.7, 2015, https://doi.org/10.14400/jdc.2015.13.7.249
  2. 간경변증 환자의 식이이행 영향요인 vol.23, pp.3, 2016, https://doi.org/10.5953/jmjh.2016.23.3.179
  3. 간경변증 환자의 자가간호이행 관련 요인: 증상경험, 지각된 건강상태 및 질병상태를 중심으로 vol.25, pp.3, 2012, https://doi.org/10.7739/jkafn.2018.25.3.165
  4. Analysis of mortality prognostic factors using model for end-stage liver disease with incorporation of serum-sodium classification for liver cirrhosis complications : A retrospective cohort study vol.98, pp.45, 2019, https://doi.org/10.1097/md.0000000000017862
  5. 간경변증 환자의 재입원 경험에 영향을 미치는 요인 vol.21, pp.5, 2020, https://doi.org/10.5762/kais.2020.21.5.111